T-cell Immunotherapy: Clinical Trial Tracker

  • ID: 3786731
  • Clinical Trials
  • Region: Global
  • Roots Analysis
1 of 4
Research Institutions Have Played a Critical Role in Maturing the Design and Development of Novel CAR-Ts, TCRs and TILs

FEATURED COMPANIES

  • Adaptimmune
  • Cell Therapy Catapult
  • Immatics
  • Mie University
  • Seattle Genetics
  • Theravectys
  • MORE
After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. These promising therapeutic strategies, developed under the banner of T-cell immunotherapies, are set to hit the market in the near future.

T-cells, also named as the soldiers of the immune system, are featured with specificity and functionally combat infections, cancerous cells and other foreign entities. High therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy.

With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time, expertise and effort, have played a critical role in maturing the design and development of novel CAR-Ts, TCRs and TILs. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products.

Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania/The Children’s Hospital of Philadelphia), JCAR017 (Juno Therapeutics/Seattle Children’s Hospital), KTE-C19 and HPV-16 E6 TCR (Kite Pharma/National Cancer Institute), CD19-CAR (Takara Bio/Jichi Medical University) and LN-144 (Lion Biotechnologies/National Cancer Institute).

The primary objective of this report is to capture details on the various clinical trials that are currently underway in the field of T-cell Immunotherapy. We have identified a number of T-cell Immunotherapy products and clinical trials that are either being conducted or planned to be conducted for each of these products. For each specific product, we have provided the following information:

- Primary Drug
- Highest Phase of Development
- Developer/Licensee
- Target Antigen

For each specific trial, we have provided the following information:

- Indication
- Type of Indication
- Sponsor/Collaborator
- Type of Sponsor
- Trial Title
- Trial Objective
- Trial Phase
- Trial Status
- Start Date
- End Date
- Enrolment
- Age Range
- Inclusion Criteria
- Exclusion Criteria
- StudyDesign
- PrimaryEndpoint
- SecondaryEndpoint
- Treatment Arm(s)
- Location(s)
- Trial Results (if known)

Research Methodology

The data presented in this report has been gathered via secondary research. The secondary sources of information include:

- Clinical trial registries
- Clinicaltrials.gov
- International Clinical Trials Registry Platform (ICTRP)
- EU Clinical Trials Register (EU CTR)
- Chinese Clinical Trial Register (ChiCTR)
- Annual reports
- Investor presentations
- SEC filings
- Company websites
- Conference websites
- Industry analyst's views

The focus has been on capturing the details on completed and ongoing clinical trials for T-cell immunotherapy. The report also provides an in-depth analysis of the competitive landscape for both pipeline molecules and clinical trials. The analysis is solely based on our knowledge and research gathered from various secondary sources of information.

Note on formats: This product is delivered as an Excel file.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adaptimmune
  • Cell Therapy Catapult
  • Immatics
  • Mie University
  • Seattle Genetics
  • Theravectys
  • MORE
1. Market Overview

2. Dashboard: Pipeline and Trial Analysis

3. CAR-T Clinical Development: Trial Details

4. TCR Clinical Development: Trial Details

5. TIL Clinical Development: Trial Details

6. Market Forecast: Assumptions

7. Market Forecast, 2015-2030

8. Preclinical Development

9. Inclusion / Exclusion Criteria

10. Abbreviations

Figure 1 T-cell Immunotherapy Products in Clinical Development: Distribution by Type of Therapy

Figure 2 T-cell Immunotherapy Trialsin Clinical Development: Distribution by Type of Therapy

Figure 3 T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development

Figure 4 T-cell Immunotherapy Products in Clinical Development: Distribution by Phase of Development and Type of Therapy

Figure 5 T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area

Figure 6 T-cell Immunotherapy Products in Clinical Development: Distribution by Therapeutic Area and Type of Therapy

Figure 7 T-cell Immunotherapy Products in Clinical Development: Distribution by Target in the CAR-T Market

Figure 8 T-cell Immunotherapy Products in Clinical Development: Distribution by Targets in the TCR Market

Figure 9 T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for CAR-T Therapy

Figure 10 T-cell Immunotherapy Products in Clinical Development: Distribution by Industrial Developers for TCR Therapy

Figure 11 T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development

Figure 12 T-cell Immunotherapy Trials in Clinical Development: Distribution by Phase of Development and Type of Therapy

Figure 13 T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area

Figure 14 T-cell Immunotherapy Trials in Clinical Development: Distribution by Therapeutic Area and Type of Therapy

Figure 15 T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status

Figure 16 T-cell Immunotherapy Trials in Clinical Development: Distribution by Trial Status and Type of Therapy

Figure 17 T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship

Figure 18 T-cell Immunotherapy Trials in Clinical Development: Distribution by Sponsorship and Type of Therapy

Figure 19 T-cell Immunotherapy Trials in Clinical Development: Distribution by Region

Figure 20 T-cell Immunotherapy Trials in Clinical Development: Distribution by Region and Type of Therapy

Figure 21 T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries

Figure 22 T-cell Immunotherapy Trials in Clinical Development: Distribution by G7 Countries and Type of Therapy

Market Forecast Analysis

Figure A T-cell Immunotherapy Market Forecast, 2015-2030

Figure B T-cell Immunotherapy Market, Share of Sub-segments: Base Scenario 2020, 2025 and 2030 (USD Million)

Table 1 CAR-T Clinical Development: Pipeline Details

Table 2 TCR Clinical Development: Pipeline Details

Table 3 TIL Clinical Development: Pipeline Details

Table 4 Preclinical Development

Market Forecast Analysis

Table A Market Forecast: Assumptions

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Abramson Cancer Center of the University of Pennsylvania
- Adaptimmune
- Affiliated Hospital to Academy of Military Medical Sciences
- Agency for Science, Technology and Research, China
- Albert Einstein College of Medicine, Yeshiva University
- Alex's Lemonade Stand Foundation
- Altor Biosciences
- Amgen
- Anhui General Hospital of Armed Police Forces
- Anhui Medical University & Hospital
- AstraZeneca/MedImmune
- Atreca Therapeutics
- Autolus
- Baxalta
- Beijing Doing Biomedical
- Bellicum Pharmaceuticals
- Bristol Myers Squibb
- CARsgen Therapeutics
- CLL Global Research Foundation Alliance
- California Institute of Technology
- Cancer Prevention Research Institute of Texas
- Cancer Research UK
- Celdara Medical
- Celgene
- Cell Therapy Catapult
- Cellectis
- Cellular Biomedicine Group
- Celyad
- Center for Cell and Gene Therapy, Baylor College of Medicine
- Changzheng Hospital
- Children's Mercy Hospital, Kansas City
- Chinese PLA General Hospital
- Christie Hospital NHS Foundation Trust
- City of Hope Medical Center
- Clinica Universidad de Navarra
- Conkwest
- Copenhagen University Hospital
- Cornell Weill Medicine, Cornell University
- Dana-Farber Cancer Institute
- Duke University Medical Center
- Erasmus Medical Center
- Fate Therapeutics
- First Hospital of Jilin University
- Five Prime Therapeutics
- Formula Pharmaceuticals
- Fred Hutchinson Cancer Research Center
- Fuda Cancer Hospital
- Fudan University Shanghai Cancer Center
- Glaxo Smith Kline
- H. Lee Moffitt Cancer Center and Research Institute
- Hadassah Medical Organization
- Harlev Hospital
- Hefei Binhu Hospital
- Hoag Memorial Hospital Presbyterian
- Huazhong University of Science and Technology
- Immatics
- Immunocore
- Intrexon Corporation
- JW Biotechnology
- James and Esther King Biomedical Research Program
- Janssen Pharmaceuticals
- Jichi Medical University
- John Wayne Cancer Institute
- Jonsson Comprehensive Cancer Center
- Juno Therapeutics
- Karolinska University Hospital
- Key Biologics
- King’s College London
- Kite Pharma
- Leiden University
- Leukaemia Lymphoma Research
- Lion Biotechnologies
- Lion TCR
- M.D. Anderson Cancer Center
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association
- MaxCyte Therapeutics
- MediGene
- Memorial Sloan Kettering Cancer Center
- Mie University
- Military Medical University
- Molmed S.p.A
- Mustang Bio
- Nantes University & Hospital
- Nantworks
- National Cancer Institute
- National Health and Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institutes of Health
- Novartis
- Oxford BioMedica
- Peking University
- PersonGen Biomedicine
- Peter MacCallum Cancer Centre
- Pfizer
- Poseida Therapeutics
- Precision BioSciences
- Prometheus
- RenJi Hospital
- Roger Williams Medical Center
- Roswell Park Cancer Institute
- Royal Adelaide Hospital Cancer Centre
- San Raffaele Hospital
- Seattle Children's Hospital
- Seattle Genetics
- Servier
- Shanghai GeneChem
- Shanghai Jiao Tong University
- Shanghai Tongji Hospital and University
- Sheba Medical Center
- Shenzhen Institute for Innovation and Translational Medicine
- Shenzhen Second People's Hospital
- Shionogi
- Sidney Kimmel Comprehensive Cancer Center
- Singapore General Hospital
- Sinobioway Cell Therapy
- Sirtex Medical
- Solving Kid’s Cancer
- Southwest Hospital
- St. Luke's Medical Center
- Sun Yat-Sen University
- Swedish Cancer Society
- TILT Biotherapeutics
- TNK Therapeutics (wholly owned subsidiary of Sorrento Therapeutics)
- Takara Bio
- Texas Children's Hospital
- The EVAN Foundation
- The First People's Hospital of Hefei
- The Methodist Hospital System
- The Netherlands Cancer Institute
- The Second Military Medical University
- The Third Military Medical University
- Theravectys
- Tianjin Medical University Cancer Institute and Hospital
- UNC Lineberger Comprehensive Cancer Center
- Universal Cells
- University College London
- University Health Network, Toronto
- University of Colorado
- University of Connecticut
- University of Florida
- University of Manchester
- University of Maryland Greenebaum Cancer Center
- University of Pennsylvania
- University of Southern California
- University of Zurich
- Unum Therapeutics
- Uppsala University
- ViroMed
- West China Hospital, Sichuan University
- WuXi AppTec
- Wuhan General Hospital of Guangzhou Command
- Xinqiao Hospital of Chongqing
- Xuzhou Medical College
- Zhejiang General Hospital of Armed Police
- Zhujiang Hospital
- Ziopharm Oncology
- bluebird bio
- iCarTAb BioMed
- iCell Therapeutics
Note: Product cover images may vary from those shown
5 of 4
Question What format is this product delivered in?
Answer This product is delivered as an EXCEL file.
Note: Product cover images may vary from those shown
Adroll
adroll